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Neurobiology of Disease
Response of a Neuronal Model of Tuberous Sclerosis to
Mammalian Target of Rapamycin (mTOR) Inhibitors: Effects
on mTORC1 and Akt Signaling Lead to Improved Survival
and Function
Lynsey Meikle,1 Kristen Pollizzi,1 Anna Egnor,1 Ioannis Kramvis,2Heidi Lane,3Mustafa Sahin,2 and
David J. Kwiatkowski1
1Division of Translational Medicine, Department of Medicine, Brigham andWomen’s Hospital and 2Department of Neurology, Children’s Hospital,
Harvard Medical School, Boston, Massachusetts 02115, and 3Novartis Institutes for BioMedical Research, Oncology Basel, Novartis Pharma AG, CH-4002
Basel, Switzerland
Tuberous sclerosis (TSC) is a hamartoma syndrome attributable tomutations in either TSC1 or TSC2 in which brain involvement causes
epilepsy, mental retardation, and autism. We have reported recently (Meikle et al., 2007) a mouse neuronal model of TSC in which Tsc1
is ablated in most neurons during cortical development. We have tested rapamycin and RAD001 [40-O-(2-hydroxyethyl)-rapamycin],
both mammalian target of rapamycin mTORC1 inhibitors, as potential therapeutic agents in this model. Median survival is improved
from 33 d to more than 100 d; behavior, phenotype, and weight gain are all also markedly improved. There is brain penetration of both
drugs, with accumulation over time with repetitive treatment, and effective reduction of levels of phospho-S6, a downstream target of
mTORC1. In addition, there is restoration of phospho-Akt and phospho-glycogen synthase kinase 3 levels in the treatedmice, consistent
with restoration of Akt function. Neurofilament abnormalities, myelination, and cell enlargement are all improved by the treatment.
However, dysplastic neuronal features persist, and there are onlymodest changes in dendritic spine density and length. Strikingly, mice
treated with rapamycin or RAD001 for 23 d only (postnatal days 7–30) displayed a persistent improvement in phenotype, with median
survival of 78 d. In summary, rapamycin/RAD001 are highly effective therapies for this neuronal model of TSC, with benefit apparently
attributable to effects on mTORC1 and Akt signaling and, consequently, cell size and myelination. Although caution is appropriate, the
results suggest thepossibility that rapamycin/RAD001mayhavebenefit in the treatmentofTSCbraindisease, including infantile spasms.
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Introduction
Tuberous sclerosis complex (TSC) is a clinically devastating neu-
rocutaneous syndrome in which benign tumors termed hamar-
tomas develop in multiple organ systems (Gomez et al., 1999;
Curatolo, 2003; Crino et al., 2006). Neurological manifestations
are a predominant clinical feature and include early-onset epi-
lepsy, mental retardation, developmental delay, and autism (Ess,
2006; Marcotte and Crino, 2006; Holmes and Stafstrom, 2007;
Winterkorn et al., 2007). Most neurological symptoms are
thought to be attributable to the occurrence of cortical tubers,
which typically form at the gray–white matter junction. The lam-
inar structure within these lesions is severely disrupted with oc-
currence of poorly differentiated giant cells, dysplastic neurons
and astrocytes, and a variety of reactive cells (Huttenlocher and
Wollmann, 1991; Ess, 2006). The number and location of cortical
tubers, as well asmore generalized cortical abnormalities, and the
timing of onset and duration of infantile spasms all appear to
have some relationship to the severity of the neurological mani-
festations that are seen in TSC patients (Doherty et al., 2005;
Marcotte and Crino, 2006; Winterkorn et al., 2007).
TSC is attributable to inactivating mutations in either the
TSC1 or the TSC2 gene and segregates in an autosomal dominant
manner (Cheadle et al., 2000). TSC1 mutations account for 20–
25% of all mutations identified, whereas TSC2 mutations ac-
count for the remainder. TSC1 disease is less severe than TSC2
disease inmultiple respects (Jones et al., 1999;Dabora et al., 2001;
Sancak et al., 2005; Au et al., 2007; Winterkorn et al., 2007), and
this appears to be attributable to a reduced frequency of second-
hit events in the TSC1 gene compared with the TSC2 gene
(Dabora et al., 2001).
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The TSC1 and TSC2 proteins form a relatively tight stoichio-
metric complex in cells, which functions in an ancestrally con-
served signaling pathway that regulates the state of activation of
mammalian target of rapamycin (mTOR) and thereby cell
growth (Goncharova et al., 2002; Kwiatkowski et al., 2002; Inoki
et al., 2005; Tee and Blenis, 2005; Avruch et al., 2006; Sabatini,
2006). Loss of either TSC1 or TSC2 leads to elevated rheb-GTP
levels, a ras family GTPase, which interacts with the mTORC1
complex to cause its activation. mTORC1 activation leads to a
downstream kinase signaling cascade, including activation of the
S6 kinases and feedback inhibition of Akt activation (Hay, 2005;
Manning et al., 2005), as well as translational activation of a select
subset of mRNAs (Bilanges et al., 2007).
A conditional allele of Tsc1 has been developed and combined
with different brain-specific cre recombinase alleles to generate
models of TSC brain disease (Uhlmann et al., 2002; Meikle et al.,
2007). We used a synapsin I promoter-driven cre allele to gener-
ate a neuronal model of TSC1, in which recombination and loss
of the Tsc1 gene occurs in differentiating neurons (Meikle et al.,
2007). These mice develop several pathologic features seen in
TSC tubers, including enlarged and dysplastic neurons, which
can occur ectopically in the cortex, persistently reducedmyelina-
tion attributable to a neuronal inductive defect, and high expres-
sion of phospho-S6 (pS6), a protein downstream of mTORC1
(Meikle et al., 2007). Clinically, these mice are hyperactive and
tremulous, with poor weight gain, development of seizures, and
median survival of 33 d. Here we present a detailed study of the
pharmacokinetics and clinical benefit of rapamycin and RAD001
[40-O-(2-hydroxyethyl)-rapamycin] [also called SDZ RAD,
everolimus (Schuler et al., 1997)] in the treatment of the TSC1
neuronal model.
Materials andMethods
Mouse procedures. As described previously (Meikle et al., 2007), mice
with these alleles began in a mixed strain background (129S4/SvJae,
C57BL/6, andCBA) but have beenmaintained as an inbred population in
our colony for3 years. Mice bearing the SynICre allele were the gener-
ous gift of Jamey Marth (University of San Diego, La Jolla, CA) (Zhu et
al., 2001). Mice were generated through matings between parents of
genotype Tsc1cc and Tsc1wSynICre or Tsc1wSynICre or
Tsc1cwSynICre. [We use c, w, and to denote the conditional (floxed),
wild-type, and null alleles of Tsc1, respectively; the formal name of the c
allele is Tsc1tm1Djk.] We use the term Tsc1null-neuron mice to denote mice
with the genotype Tsc1c SynICre or Tsc1cc SynICre. As reported pre-
viously, mice with these two genotypes have identical phenotypes and
survival (Meikle et al., 2007). Controls usually had the genotype Tsc1c
SynICre, but some were Tsc1c SynICre, Tsc1c SynICre, or Tsc1cc
SynICre. Littermate controls were used whenever possible, but all mu-
tants and controls were closely related from this inbred colony.
All procedures were performed in accordance with the Guide for the
Humane Use and Care of Laboratory Animals, and the study was ap-
proved by the Animal Care and Use Committee of Children’s Hospital.
Individual mice were killed when weight loss of 20%, greatly reduced
movement, or other signs of morbidity were seen.
Neurologic assessment was performed by an observer blinded to ge-
notype and treatment status of the mice. This included the following:
assessment of hindleg clasping behavior when suspended by the tail,
scored as absent (0) or present (1); whole-body tremor assessed by plac-
ing the palm of the hand on the back of themouse, scored on a scale from
absent (0) to severe and persistent (5); kyphosis, scored as absent (0) or
present (1); and tail position observed during a 3 min interval during
which the animal was allowed towalk freely in a confined space, scored as
normal (0), held horizontal (1), held above horizontal (2), or Straub
position (elevated highly, 3). Scores for these traits were compared using
the Fisher’s exact test (clasp, kyphosis) or the Mann–Whitney U test
(tremor, tail position) in Prism (GraphPad Software).
Mice were anesthetized, and total body weight was determined before
they were killed. The brains were rapidly removed, snap frozen in liquid
nitrogen, and stored as half brains at80°C until use. Half-brain weights
were measured in milligrams accurate to0.1 mg. Brain weight to body
weight ratios were calculated, and measurements were compared using
the Mann–Whitney U test.
DNA analyses. DNA was prepared from mouse toes/tails by standard
procedures for genotyping. Genotyping at the Tsc1 gene was performed
using a four-primer system that allows simultaneous analysis of the c, w,
and  alleles, followed by agarose gel electrophoresis (Meikle et al.,
2005). Primers that amplify a 300 bp portion of the cre recombinase gene
were used to assess the presence of the SynICre allele (Meikle et al., 2005).
Antibodies. Antibodies used were as follows: Tsc2 (C20), Akt (C20),
extracellular signal-regulated kinase 2 [ERK2 (K23)], pCofilin(S3) from
Santa Cruz Biotechnology; pS6(S240/244), pS6(S235/236), Tsc1, pA-
KT(S473), S6, Cofilin, glycogen synthase kinase (GSK) 3, and
pGSK3(S9) from Cell Signaling Technology; neuronal-specific nuclear
protein (NeuN) (MAB 377), neurofilament (MAB4245), MBP (AB980),
high- and medium-molecular-weight neurofilament from Millipore
Bioscience Research Reagents; nonphosphorylated neurofilament
(SMI311), phosphorylated neurofilament (SMI312), and MBP (SMI99)
from Sternberger Monoclonals.
Immunoblotting.Mice were killed, and brains were harvested as above.
Each frozen half brain was homogenized in 5 volume TBSV lysis buffer
(in mM: 20 Tris-Cl, pH 7.5, 140 NaCl, 10 NaF, 1 Na3VO4, and 1 EDTA)
with 0.1% Triton X-100, 10 mM -glycerol phosphate, 1% phosphatase
inhibitor cocktail 1 (Sigma), and 1% phosphatase inhibitor cocktail 2
(Sigma). Any solid insoluble matter was removed by centrifugation at
15,000  g at 4°C for 10 min, and the supernatant was mixed with
Laemli’s SDS-sample buffer. Samples were put through a 22 gauge nee-
dle, boiled, and centrifuged before loading. Proteins were separated by
electrophoresis on 4–12% Bis-Tris gels (Novex) and transferred onto
trans-blot nitrocellulosemembranes. Coomassie stainingwas performed
to confirm that the samples were loaded equally. The membranes were
blocked in 5% nonfat dry milk in PBS, pH 7.4, with 0.1% Tween 20
(PBS–Tween) for 1 h at room temperature. Primary antibodies were
diluted in blocking solution, and membranes were incubated overnight
at 4°C or 1 h at room temperature. The primary antibody was removed,
and the blots were washed in PBS–Tween and then incubated for 1 h at
room temperature in horseradish peroxidase-conjugated secondary an-
tibodies (Santa Cruz Biotechnology). Reactive proteins were visualized
using SuperSignal West Pico chemiluminescence reagent (Pierce) and
exposure to x-ray film (BioMaxMR; Eastman Kodak). All immunoblots
shown in one row of a figure are from the same gel-blot exposure.
Histological preparation, immunohistological staining, and microscopy.
For immunohistochemistry, mice at ages postnatal day 21 (P21) to P100
were anesthetized, and transcardiac perfusion was performed using PBS,
followed by 4% paraformaldehyde (PFA) in PBS (Boston BioProducts).
Whole brains were then removed and postfixed overnight at 4°C in 4%
PFA solution. Fixed brains were then cryoprotected in 30% sucrose in
PBS for 1–14 d at 4°C, and coronal sections were cut at 50 m using a
Microm K400 Fast Freezing Unit and HM 450 Sliding Electronic Mic-
rotome and were then stored in PBS at 4°C until use (Meikle et al., 2007)
Free-floating sections were incubated in blocking solution (PBS, 0.1%
Triton X-100, and 5% normal goat serum) for 1 h at room temperature,
followed by incubation with primary antibody overnight at 4°C. After
three 20-min PBSwashes, sections were incubated in secondary antibody
solution containing Alexa Fluor 568 goat anti-rabbit/anti-mouse IgG/
IgM orOregonGreen 488 goat anti-rabbit/anti-mouse IgG (Invitrogen),
for 1 h at room temperature. After two washes in PBS, for some sections,
0.5 g/ml Hoechst 33258 was added to each well for 5 min at room
temperature, and the sections were then washed twice in PBS, mounted
onto positively charged slides, and coverslipped with antifade medium
(Fluoromount-G; Southern Biotechnology Associates). Control sections
were done with omission of one or both primary antibodies, adding both
secondary antibodies, to establish specificity. Slides were viewed on a
Nikon TE2000-E inverted microscope. Illumination wavelength, inten-
sity, and exposure times were selected using a dual filter-wheel apparatus
containing an electronically controlled shutter and filters for the different
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fluorophore wavelengths (Lambda 10-2; Sutter Instrument). Digital im-
ages were captured using an Orca-II ER cooled CCD camera
(Hamamatsu) and MetaMorph (Molecular Devices). Digital images
were then processed and analyzed using Adobe Photoshop (Adobe Sys-
tems), including pseudocolorization.
Standard histology sections were prepared after Bouins fixation at
room temperature. After hematoxylin and eosin staining, slides were
viewed on a Nikon Eclipse E400 microscope, and images were captured
using Spot software version 4.0.5.
For all histological and immunostaining observations, a minimum of
three (range of 3–12) pairs of mutant and control mice were examined
from stereotactically matched brain sections.
Confocal images were captured using a Zeiss LSM510 META two-
photon confocal microscope using 20 and 63 objectives. For cell size
determination and other images, a Z-stack of confocal images at 0.5 m
intervals were collected from the somatosensory cortex at layer V (2 to
2.2 mm from bregma and 3.2–3.4 mm lateral to midline) for each of at
least two matched mutant and control mice. Images were examined us-
ing NIH ImageJ software 1.31v to calculate cell size in square microme-
ters after manual drawing of cell margins. All SMI311-positive
(SMI311) cells in a 20 field weremeasured, independent of pS6 stain-
ing, for a minimum of eight cells per field, and the largest eight cells were
included in the measurements. Measurements were compared using the
Mann–Whitney U test.
To quantify dendritic orientation as a measure of neuronal dysplasia,
the direction of the apical dendrite of each SMI311 pyramidal neuron
in layer V of a section of somatosensory cortex was assessed. Neurons
with apical dendrites oriented within 15° of a vertical line to the pia from
the cell center were considered normal. Neurons with apical dendrites
oriented outside of this 15° range in either direction were considered to
have aberrant orientation.
Drug handling, administration, and pharmacokinetic analyses. Rapa-
mycin was obtained from LC Laboratories, dissolved at 20 mg/ml in
ethanol, and stored at  20°C for up to 1 month. Before each adminis-
tration, rapamycin was diluted in 5% Tween 80, 5% polyethylene glycol
400 (0.5–1.5 mg/ml). Rapamycin was given at 6 mg/kg intraperitoneally
every 2 d. RAD001was provided byNovartis in a proprietary vehicle at 20
mg/ml. Before each administration, RAD001 was diluted in water to
0.5–2 mg/ml and was given at either 3 or 6 mg/kg intraperitoneally every
2 d. Both drugs were given beginning at P7–P9, every other day, for up to
92 d (P100).
For pharmacokinetic analyses, each drug was given once or multiple
times intraperitoneally to control, nonmutant mice from the Tsc1 syn-
apsin–cre colony. Mice were killed at 1, 4, 12, 24, or 48 h after drug
administration, blood was collected in acid–citrate–dextrose solution,
and plasma was isolated by centrifugation at 5000 rpm for 5min. Organs
were then quickly removed and frozen at  80°C. Organ extracts were
prepared by homogenization in 5 (w/v) of PBS until a fine suspension
was achieved. This solution was clarified by centrifugation at 12,000 g
for 15 min and then frozen at 80°C until ready for assay. Rapamycin
levels were determined after solid-phase extraction using liquid chroma-
tography/tandemmass spectrometry (LC/MS/MS) on an API-2000 (Ap-
plied Biosystems) instrument in the Clinical Laboratories, Children’s
Hospital, Boston. This is a Clinical Laboratory Improvement
Amendments-certified laboratory that routinely determines rapamycin
levels on pediatric samples. RAD001 levels were determined using LC/
MS/MS by Ann Brown at Novartis Biomedical Research Institute (Cam-
bridge, MA). Briefly, tissue lysates, separated plasma, and calibration
standards were extracted using the acetonitrile (ACN) protein precipita-
tion technique. Reverse-phase chromatography (column: ACEC18 30
2.1 mm, 3 m) was used using a gradient elution with 0.1% HCOOH/
water and 0.1% HCOOH/ACN as mobile phase A and B, respectively.
The analyses were performed in electrospray-positive mode using mul-
tiple reaction monitoring conditions on a Sciex API 4000 instrument
(Applied Biosystems).
DiI staining of neurons and dendritic spine measurements. Spine tracing
and analysis was performed as described previously (Murai et al., 2003).
Briefly, anesthetized mice were transcardially perfused with PBS and
fixed with 4% PFA at 2 ml/min for 5 min. Whole brains were removed
and postfixed for 30 min in 4% PFA on ice. Brains were then embedded
in 3% agarose and sectioned at 150 m using a vibrating-blade mic-
rotome (Leica). Introduction of 1,1-dioctadecyl-3,3,3,3-tetramethy-
lindocarbocyanine perchlorate (DiI) (Invitrogen)-coated gold particles
was performed using the Helios Gene-Gun (Bio-Rad) at 80 psi. Coated
particles were prepared by mixing 20 mg of gold particles with 5 mg of
DiI. After gene gun particle injection, sections were placed in 4%PFA for
20 h to allow DiI diffusion along the cell membrane. Sections were then
imaged by confocal microscopy. A Z-stack of confocal images at 0.5 m
intervals was collected from the somatosensory cortex in layer V. Spine
analysis was performed usingMetaMorph software (Molecular Devices).
Spine lengths were measured from the tip to the intersection of the spine
with the dendrite. Measurements of spine length (n 856–1742 spines)
and spine density (n  10–19 dendrites) were compared using the
Mann–Whitney U test in Prism (GraphPad Software).
Results
Pharmacokinetics of rapamycin and RAD001 in the brain
We explored the pharmacokinetics and pharmacodynamics of
rapamycin and RAD001 to help define an effective dose of
each compound for treatment of the previously described
Tsc1null-neuronmice (Meikle et al., 2007). These drugs were chosen
for study because they are both orally formulated for administra-
tion in humans, and both drugs are known to inhibit the kinase
activity of mTOR by binding to FK506 binding protein 12
(FKBP12), which then binds to themTORC1 complex (Brown et
al., 1994). In addition, because the drugs are structurally different
(Schuler et al., 1997), a direct comparison of both compounds
was performed to determine whether they had different pharma-
cologic properties, particularly their relative penetration into the
brain. Although both rapamycin and RAD001 can be given orally
to older mice, we administered both drugs intraperitoneally be-
cause it is difficult to perform gavage on P7mice, the age at which
we chose to initiate treatment.
A single dose of either drug given at 6 mg/kg intraperitoneally
to control mice aged P30–P45 led to substantial drug levels in
plasma, liver, and brain (Fig. 1A,D). Brain levels remainedmark-
edly lower than systemic levels at all time points, consistent with
an effect of the blood–brain barrier in reducing penetration into
the CNS. Nonetheless, brain levels of each drug remained above
the level required to inhibit mTORC1 (10 ng/ml for either drug
when applied to cells in vitro) throughout the 48 h period after
administration (rapamycin, 38.6 ng/g; RAD001, 40.5 ng/g; at 48 h
after drug administration). Note also that therapeutic trough lev-
els for each drug in humans are 3–20 ng/ml in whole blood. Both
drugs displayed higher levels in nearly all cases when given every
other day over a 3 week period (12 doses) compared with a single
dose (Fig. 1B,E). Brain levels 48 h after the last of 12 doses were
rapamycin at 88.4 ng/g and RAD001 at 48.9 ng/g. In an initial
pharmacodynamic analysis, pS6(S235/236) and pS6(S240/244)
levels were assessed by immunoblot analysis of whole-brain ly-
sates from the Tsc1null-neuron mice, at 24 h and 48 h after the last
treatment at 6 mg/kg intraperitoneally in a 12 dose every other
day of treatment regimen. Phosphorylation of S6 at both sites
returned to control (or lower) levels 24 h after the last dose (Fig.
1 I) and remained low at 48 h (data not shown). However, this
normalization of pS6 levels at 48 h after the last dose was not as
consistent in mice similarly treated with 3 mg/kg (data not
shown).
We also assessed whether the pharmacokinetics of these drugs
was different in youngermice. Liver levels were increased 3.5-fold
for rapamycin and 4.1-fold for RAD001 in P10 mice 24 h after a
single intraperitoneal injection compared with similarly treated
P30–P45 mice (Fig. 1C,F). These data indicate that overall clear-
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ance of each drug is reduced at this age. In addition, brain levels of
each drug were similar to liver levels at P10 24 h after injection
(Fig. 1C,F), indicating that the blood–brain barrier was not de-
veloped at P10.
These data indicated that penetration of rapamycin and
RAD001 into the CNSwas substantial, although it is clearlymuch
higher in younger mice. Although levels were high at P10, we
elected to use 6 mg/kg intraperitoneally every other day as our
standard dose for several reasons. First, we wanted to ensure that
we would have effective mTOR inhibition at the dose used
throughout the period of treatment, to have maximal potential
therapeutic effect. Second, although levels clearly rosewith repeat
dosing, we were concerned that these levels might be misleading
in reflecting retention of drug in a lipid compartment in the brain
or drug bound to protein, which would not be free to enter into a
complexwith FKBP12, required formTORC1 inhibition. Finally,
as noted above, mTORC1 inhibition in the brain, as assessed by
pS6 immunoblotting, was more effective at this dose than at 3
mg/kg for either drug.
Therapeutic effects of
rapamycin/RAD001 in
Tsc1null-neuron mice
Both rapamycin and RAD001, when given
intraperitoneally at 6 mg/kg every other
day beginning at P7–P9, caused dramatic
therapeutic benefit. Tsc1null-neuron mice on
these regimens demonstrated 90–100%
survival at 80 d of age, and this improve-
ment continued until the experiment was
terminated at P100 (Fig. 1G,H; note that
median survival for the untreated mutants
was 33 d). In addition, Tsc1null-neuron mice
receiving either drug displayed dramatic
clinical improvement with a marked re-
duction in clasping behavior when sus-
pended by their tails, tremor, kyphosis,
and aberrant tail position (Straub tail) (Fig.
2A–C, Table 1). Using a blinded observer
to assess these four phenotypic measures,
all four were significantly improved at all
follow-up times (P30, P60, and P100) in
both rapamycin- and RAD001-treated
mice (Table 1, p 0.01 for each compari-
son). Consistent with a marked improve-
ment in phenotype and development,
there was also an improvement in the
brain/body weight ratio after rapamycin
treatment, which was markedly elevated
(2.4-fold) in untreated Tsc1null-neuron mice
comparedwith controls (Fig. 2M). Despite
this phenotypic improvement, the weight of
rapamycin/RAD001-treated Tsc1null-neuron
mice at P30 was similar, although slightly
higher on average, to that of untreated mu-
tants (Table 1). However, with longer follow
up, significant weight gain was seen,
with rapamycin- and RAD001-treated
Tsc1null-neuron mice having average
weights of 18.1 and 19.6 g at P100 (Table
1, compared with 23.2 g in untreated
control P100 mice). Both drugs had a
similar effect in suppressing the growth
and weight gain of control mice at P30
(Table 1).
Discontinuation of either drug treatment at P30 led to sus-
tained clinical improvement for 1–2 weeks, followed by a gradual
clinical deterioration (Fig. 2D, compare with C), which led to
death at amedian age of 79 d for rapamycin and 77 d for RAD001
(Fig. 1G,H). At P60, 30 d after stopping drug, rapamycin-treated
mice had significant weight gain and significant phenotypic im-
provement in clasping behavior, tremor, and tail position (all p
0.03) compared with untreated P30 mutant mice (Table 1).
Effects of treatment on cortical organization, dysplasia, cell
size enlargement, and myelination
We examined several aspects of cortical organization and neuro-
nal morphology to provide insight into the mechanism of action
of rapamycin/RAD001, following upprevious observations in the
Tsc1null-neuron mice (Meikle et al., 2007). Because these two com-
pounds had equivalent therapeutic effects on survival (Fig.
1G,H) and in phenotypic improvement at both P30 and P100
(Table 1, all pairwise comparisons of phenotypic measures are
Figure1. Pharmacokinetics, survival benefit, andbrain signaling effects of rapamycin andRAD001 in Tsc1null-neuronmice.A–F,
Pharmacokinetic analyses of rapamycin (A–C) and RAD001 (D–F ) in P30–P45 mice. Both drugs were given at 6 mg/kg intra-
peritoneally. SEMs are indicated. n 3 for all rapamycin measurements; n 3 for all but 5 RAD001 measurements. A, D, Drug
levels in plasma, brain, and liver. Time after a single intraperitoneal injection is shown on the x-axis. Note that y-axis is exponen-
tial.B, E, Drug levels at 24 and 48 h after single andmultiple doses.Multiple doseswere given every other day. C, F, Drug levels in
older (P30–P45) mice compared with young (P10) mice 24 h after a single intraperitoneal dose. G, H, Survival curves of
Tsc1null-neuronmice treatedwith rapamycin (G) or RAD001 (H ). Doses of each drug, periods of treatment, and numbers of treated
mice are indicated. Treatment began at P7–P9 for allmice. Note that dashed lines reflect a cohort ofmice inwhich treatmentwas
discontinued after P30. Tsc1c SynICre mice comprised 58, 78, and 61% of the rapamycin, RAD001, and untreated cohorts,
respectively. The remainder were Tsc1cc SynICre. Note that the survival of untreated Tsc1c SynICre and Tsc1cc SynICremice
were not different, with medians of 32 and 34 d, respectively (not shown). I, Immunoblot analysis of P30 brain lysates collected
24 h after the last dose of drug shows reduction of Tsc1 protein levels (*) in all Tsc1null-neuron (mutant) brain lysates and reduction
in pS6(240/4) and pS6(235/6) in lysates from treated mutant mice. AKT and ERK2 are loading controls. Mut, Mutant; Cont,
controls. Both rapamycin (RAP) and RAD001were given 6mg/kg intraperitoneally every other day, beginning at P7–P9. Lanes 1,
2, 6, 8, and 9 were Tsc1c SynICre; lanes 5, 7, and 10 were Tsc1cc SynICre; lanes 3 and 4 were Tsc1c SynICre.
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nonsignificant), we focused these studies on mice treated with
rapamycin.
Analysis of cortical sections from the rapamycin-treated
Tsc1null-neuron mice showed several aspects of improvement (Fig.
2E–L). First, treatment of themutantmice with rapamycin led to
a marked reduction in the extent of expression of pS6(S235/236)
compared with untreated controls (Fig. 2E–G). This was appar-
ent throughout the cortex but was most marked in a subset of
enlarged pS6 cells seen at the base of the cortex (Fig. 2F, *) and
in cortical layer V in the mutants. A considerable decrease in
levels of pS6(S235/236) was also noted in the thalamus and CA3
region of the hippocampus in the treatedmutantwhen compared
with untreated mutants (see further below). Interestingly, these
abnormal pS6-positive cells reappearedwithin 2weeks of discon-
tinuation of rapamycin (Fig. 2H, *). Treatment of control mice
with rapamycin suppressed pS6(S235/236) levels even lower than
in untreated controls (Fig. 2 I). Standard histological sections also
showed that these enlarged cells weremarkedly diminished in the
rapamycin-treated mutants (Fig. 2 J–L, note * in K). However,
the mild overall cortical disorganization noted in the untreated
mutants was not affected by rapamycin treatment.
We also examined neuronal morphology in the treated mice,
using the SMI311 antibody against nonphosphorylated neuro-
filament to identify a restricted neuronal population in lateral
somatosensory cortex, as done previously (Meikle et al., 2007)
(Fig. 3A–J, see N for orientation). We observed that these cells
were considerably enlarged in Tsc1null-neuronmice compared with
SMI311 cells from the identical region of control mice (Fig.
3A,B,F,G). Quantitative measurement showed that there was a
considerable reduction in cell size after treatment (reduced from
1.81-fold to 1.18-fold when compared with untreated controls,
p 0.0001). However, this was a reversible phenomenon as the
enlarged SMI311 pyramidal cells reappeared when rapamycin
treatment was discontinued for 2 weeks (Fig. 3D, I,M) (increased
to 1.77-fold compared with untreated controls, p 0.02).
Thus, rapamycin was very effective at reducing cell size in
Tsc1null-neuronmice.However, despite this drastic reduction in cell
size, rapamycin treatment appeared to have little effect on the
dysplastic features of the neurons in this model (Fig. 3K,L). To
examine this quantitatively, we assessed the orientation of the
apical dendrite in SMI311 layer V neurons in somatosensory
cortex (Table 2). In control mice, nearly all (96%) neurons were
polarized with a long apical dendrite that was oriented directly
(15°) toward the pial surface. In contrast, Tsc1null-neuron neu-
rons often had major dendrites that extended tangentially and
diagonally to the pia. In addition, rapamycin treatment initiated
Figure 2. Clinical and histological improvement in Tsc1null-neuron mice treated with rapamycin. A–D, Pictures of mice. Control and mutant (Tsc1null-neuron) mice with or without rapamycin
treatment are shown. Rapamycin was given 6 mg/kg intraperitoneally every other day from P7 to P9 and was discontinued at P30 in the on/off mouse. A, C, D are all P45; B is P30. Note abnormal
posture of mutant and mutant on/off treatment mice. E–I, Combined NeuN (red)–pS6(S235/236) (green) stains of base of cortex over the anterior hippocampus. P45 control, P30 mutant
(Tsc1null-neuron), P45 rapamycin-treatedmutant, P45 rapamycin-treatedmutant until P30 then taken off drug (on/off), and P45 rapamycin-treated control mouse sections are shown. Scale bar, 50
m. Imageswere collected using the confocalmicroscope on a single slice at 200with 0.7 zoom. J–L, Hematoxylin and eosin stains of the cortex demonstratemild cortical disorganization in the
mutant mouse with global cell enlargement particularly at the base of cortex (*), with improvement with treatment. Ages and treatments are as in E–G. Genotypes for mice were as follows: A, E,
I, J, Tsc1c SynICre; F, L, Tsc1c SynICre; B, C,D, G,H, K, Tsc1cc SynICre.M, Brain weight to body weight ratio in these same groups of mice, all at P30. Each point is a different mouse; the line
indicates the mean. p 0.01 for each group compared with untreated mutant. Numbers and genotypes of mice were as follows: Mutant, six Tsc1c SynICre; Control, three Tsc1c SynICre;
Mutant Rap, three Tsc1cc SynICre, three Tsc1c SynICre; Control Rap, two Tsc1c SynICre.
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at P7 did not reduce the percentage of SMI311 neurons with
abnormally oriented dendrites in Tsc1null-neuron mice (Table 2,
38.8% without treatment, 43.5% with rapamycin treatment).
Tsc1null-neuron mice have impaired myelination to the extent
that the cerebral cortex of a P30 mouse had only a faint patchy
myelin stain, consistent with reduced myelin synthesis by oligo-
dendrocytes (Meikle et al., 2007) (Fig. 4B). Rapamycin treatment
effectively restored myelination in the Tsc1null-neuron brain (Fig.
4A–J; compare C with A, B; compare H with F, G). Although
restoration of myelin was seen throughout the brain, the most
dramatic improvement was seen in the cortex in which MBP
myelin sheaths were evident coating radiating fibers extending
out from the base of the cortex and in the pericallosal portion of
the retrosplenial granular region (Fig. 4C). An improvement in
myelination was also seen in the hippocampus (Fig. 4H). Double
staining with pS6(S235/236) and MBP showed that there was a
clear concordance between reduction in pS6 levels and restora-
tion of myelin expression, as seen in the CA3 region of the hip-
pocampus (Fig. 4K–O). Despite reducing pS6 levels to a subnor-
mal level, rapamycin appeared to have little effect onmyelination
in the treated controls (Fig. 2E, J,O).
Biochemical and signaling effects of rapamycin treatment in
the Tsc1null-neuronmice
Recent studies indicate that an important signaling effect in cells
lacking Tsc1 or Tsc2 is a reduction in activation of Akt in re-
sponse to normal stimuli (Zhang et al., 2003; Harrington et al.,
2004; Shah et al., 2004). There has been speculation that this
effect might have significant pathophysiological consequences in
addition to that of mTORC1 activation in cells lacking Tsc1/Tsc2
(Manning et al., 2005). We assessed this possibility in brain ex-
tracts from the Tsc1null-neuron mice (Fig. 5A). Whereas pS6(S235/
236) and pS6(S240/244) levels were significantly increased in the
mutant mice, pAkt(S473) levels were reduced compared with
controls. Moreover, rapamycin treatment led to restoration of
pAkt(S473) levels, just as it decreased pS6 levels at both phos-
phorylation sites. Both of these effects were reversed when rapa-
mycin treatment was discontinued. We also explored down-
stream signaling effects of this suppression of Akt signaling in the
Tsc1null-neuron mice. pGSK3(S9) levels were also reduced in the
Tsc1null-neuronmice and were reversed by treatment with rapamy-
cin (Fig. 5B), consistent with diminished signaling downstream
of Akt.
Cytoskeletal abnormalities have also been reported in cells
and neurons lacking Tsc1/Tsc2 (Lamb et al., 2000; Goncharova et
al., 2004). Levels of phosphorylated neurofilament, neurofila-
ment heavy chain, and neurofilament medium chain were all
increased in the Tsc1null-neuronmice compared with controls (Fig.
5C). Furthermore, these effects on the neuronal cytoskeleton
were effectively reversed by rapamycin treatment. In contrast, we
found no consistent evidence of significant alterations in pCofi-
lin(S3) levels in the Tsc1null-neuron mice compared with controls
(Fig. 5C).
Dendritic spine abnormalities in the Tsc1null-neuron mice
Because of a previous report of significant effects of loss of Tsc1 or
Tsc2 on dendritic spine density, shape, and length in in vitro
hippocampal slice cultures (Tavazoie et al., 2005), we examined
dendritic spine morphology in the Tsc1null-neuron mice including
in response to rapamycin treatment, using biolistics with DiI to
label a small subset of cortical neurons. Confocal microscopy
demonstrated that robust staining was achieved in select neurons
(Fig. 6A). Quantitative analysis of spine density and length indi-
cated that dendrites of cortical neurons from Tsc1null-neuron mice
had a significant ( p  0.05), 22% reduction in spine density
comparedwith neuronal dendrites from controlmice (Fig. 6B,C,
Table 3). However, there was no significant difference in spine
length in neurons from these two types of mice. In response to
rapamycin treatment of the Tsc1null-neuronmice, there was a small
(10%) increase in spine density ( p value was nonsignificant) to-
ward a normal density. In addition, there was an 9% increase in
spine length in the rapamycin-treated Tsc1null-neuron mice com-
pared with both mutant and control mice (Table 3, p 0.002).
Discussion
The Tsc1null-neuron mice studied here replicate several of the clin-
ical and pathologic features seen in TSC patients (Huttenlocher
and Wollmann, 1991; Crino, 2004; Zikou et al., 2005; Ess, 2006;
Marcotte and Crino, 2006; Holmes and Stafstrom, 2007). There
are enlarged and ectopic cells, with prominent dysplasia, andhigh
Table 1. Neurologic features in Tsc1null-neuronmice according to age and treatment
Genotype class Treatment Age n Weight (g) Weight SD Clasp Tremor Kyphosis Tail
% Tsc1c SynICre
46% Mutant None P30 16 9.87 1.59 0.63 3.28 0.81 2.73
65% Mutant Rapamycin P30 17 10.27 2.05 0 0.12 0 0.88
88% Mutant RAD001 P30 17 11.14 1.14 0 0.26 0 1.24
92% Mutant Rapamycin P60 12 14.39 2.68 0 0.42 0.17 0.83
86% Mutant rap-P30 P60 9 16.13 2.48 0 1.94 0.67 1.14
71% Mutant Rapamycin P100 14 18.13 1.84 0 0.64 0.14 0.79
82% Mutant RAD001 P100 11 19.59 2.30 0.09 1.00 0.27 0.73
% Tsc1c SynICre
89% Control None P30 10 20.32 2.85 0 0.35 0 0.30
100% Control Rapamycin P30 4 11.50 0.27 0 0.25 0 0
86% Control RAD001 P30 7 12.66 2.33 0.14 0.14 0 0.14
57% Control Rapamycin P60 7 18.39 2.31 0 0.36 0 0.57
75% Control Rapamycin P100 9 19.56 2.25 0 0.39 0 0.56
78% Control RAD001 P100 9 20.76 2.91 0 0.22 0.22 0.44
Mutant refers to Tsc1null-neuronmice. Mutants had genotypes Tsc1c SynICre or Tsc1cc SynICre; % Tsc1c SynICre is shown in the first column for mutants. Controls had genotypes Tsc1c SynICre, Tsc1c SynICre, Tsc1cc SynICre,
Tsc1c SynICre; % Tsc1c SynICre is shown in the first column for controls. All treatments were 6 mg/kg intraperitoneally every other day, beginning at P7–P9. Rapamycin on/off mice were treated until P30, and then drug was
discontinued; all otherswere treated continuously. Average values forweight in grams and standard deviation (SD) are shown. Average values for clasping, tremor, kyphosis, and tail position scores are shownandwere assessed as described
in Materials and Methods. Tremor and tail position were scored on 0–5 and 0–3 scales, respectively. Clasping and kyphosis were assessed on a binary 0 (absent) or 1 (present) scale. Note that all neurologic scores as well as weight were
significantly different ( p 0.003 for each) between untreated mutant and control mice at P30. All neurologic scores, but not weight, were also significantly different ( p 0.003 for each) between P30 mutant and rapamcyin- or
RAD001-treated P30mice. There was no significant difference between weight or any neurologic score between rapamycin- and RAD001- treatedmice at either P30 or P100. There was a significant difference between rapamycin-treated
P60 and rapamycin-treated 22 d only P60 (rap on/off) mice in both tremor ( p 0.0003) and kyphosis ( p 0.02).
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level expression of pS6, as well as reducedmyelination (Meikle et
al., 2007). The mice show a progressive neurologic phenotype
with tremor, hyperactivity, poor weight gain, seizure tendency,
and limited survival. The current work demonstrates the marked
therapeutic benefit of both rapamycin andRAD001 to effect both
dramatic clinical and substantial histologic improvement in this
TSCmodel.Mice treated at 6mg/kg intraperitoneally every other
day with either drug enjoyed survival out past 100 d in the vast
majority of mice, with persistent improvement in clinical pheno-
type, weight gain, and behavior and complete absence of sponta-
neous clinical seizures. This study provides the first evidence that
rapamycin/RAD001 can induce significant physiologic im-
provement in vivo through effects on postmitotic cells, in this
case, neurons that are lacking Tsc1. Because loss of Tsc1 leads
to reduced stability and functional loss of Tsc2 (Chong-
Kopera et al., 2006; Meikle et al., 2007) and cells lacking either
Tsc1 or Tsc2 have identical activation of mTORC1 (Zhang et
al., 2003; Inoki et al., 2005), rapamycin would very likely have
similar benefit in a Tsc2 neuronal model. It is notable that
similar therapeutic benefit with reduction in cell size has been
seen using CCI-779 [42 (3-hydroxy-2-(hydroxymethyl)-2-
methylpropanoate)rapamycin], a rapamycin prodrug, in the
treatment of a mouse brain model in which the phosphatase
and tensin homolog PTEN is deleted (Kwon et al., 2003).
We explored several aspects of brain pathology in these mice
to attempt to determine the cause of the clinical improvement
that was seen. A reduction in cell size, improvement in biochem-
ical and signaling profiles, reduction in neurofilament expression
and phosphorylation, and markedly improved myelination were
all seen. Strikingly, major clinical benefit persisted for several
Figure 3. Effects on neuronal size and orientation in Tsc1null-neuronmice of treatmentwith rapamycin.A–J, Paired images are shown for P45 control, P30mutant (Tsc1null-neuron), P45 rapamycin-
treated mutant, and P45 rapamycin-treated until P30 then taken off drug (on/off) mutant, and P45 rapamycin-treated control, respectively. Scale bar, 50m. All images are Z-stacked 200
confocal images. Genotypes ofmicewere as follows:A, E, F, J, Tsc1c SynICre;B,G,K, Tsc1c SynICre; C,D,H, I, L, Tsc1cc SynICre.A–E, Nonphosphorylated neurofilament (SMI311) expression
(red) and 4,6-diamidino-2-phenylindole (DAPI) (blue). F–J, Nonphosphorylated neurofilament (SMI311) expression (red)with pS6(S235/236) expression (green) and DAPI (blue) stains of lateral
cortex. Note abnormal SMI311 cells that are enlarged and dysplastic in the untreatedmutantmice. These cells have reduced cell size but not degree of dysplasia in response to rapamycin. Inmice
taken off rapamycin, there is recurrence of cell enlargement.K, L, Higher-power view of cells from imagesG andH highlight the aberrant polarity of the apical dendrite of these neurons, despite the
smaller size of the treatedmutantneuron (L). Scalebar, 10m.Both images are Z-stacked630, 1.5 zoomconfocal images.M, Cell sizemeasurements in these same five categories ofmice, from
SMI311-stained lateral cortex. Cell size is indicated in squaremicrometers. Each point is the size of one SMI311-stained neuron, with eight neurons counted permouse section. The average size and
SEM are shown. Comparisons between each of the mutant and the on/off mutant and each of the control, treated mutant, and treated control are significant at p 0.02 to0.0001. All other
comparisons have p 0.05. Numbers and genotypes of mice were as follows: Mutant, four Tsc1c SynICre; Control, four Tsc1c SynICre; Mutant Rap, three Tsc1cc SynICre; Mutant Rap
on/off, two Tsc1cc SynICre; Control Rap, two Tsc1c SynICre. N, Cortical section indicates region of cortex and orientation shown in A–J.
Table 2. Apical dendrite orientation
Genotype Treatment n sections/neurons % abnormal orientation
Control None 6/304 4.2 3.0
Control Rapamycin 6/272 9.9 2.5
Mutant None 6/293 38.8 3.5
Mutant Rapamycin 4/199 43.5 8.7
Mean  SD are shown for the percentage of SMI311 neurons in somatosensory cortex that have abnormal
orientation (15° angle of apical dendrite compared with a vertical line to the pia). Each control group is signifi-
cantly different at p 0.001 from each mutant group (one-way ANOVA with Tukey’s correction). Neither the two
control groupsnor the twomutant groups are statistically significantly different fromeachother. Genotypeswere all
Tsc1c SynICre for the untreated mutant group; all Tsc1cc SynICre for the rapamycin-treated mutants; and
Tsc1c SynICre for all control mice.
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weeks when drug treatment was discontinued. Whereas cell en-
largement and biochemical and signaling profiles reverted to
their pretreatment patternswithin 2weeks (Figs. 2H, 3I, 4N, 5A),
myelination remained intact. It is therefore likely that improved
myelination played a major role in the reduction in tremor,
ataxia, and spasticity seen in the treated mutant mice. As shown
previously (Meikle et al., 2007), this defect in myelination is not
attributable to abnormal oligodendrocyte number or distribu-
tion, but rather there is a neuronal inductive defect, which as
shown here is responsive to rapamycin/RAD001 treatment. Al-
though the precise mechanism requires additional study, it is
likely attributable to overactive mTORC1.
In contrast to the many features that were improved in this
model in response to treatment, neuronal dysplasia and neuronal
migration were both unchanged (Fig. 3K,L, Table 2). This is
consistent with completion of neuronal differentiation and cor-
tical migration before institution of rapamycin/RAD001 therapy
at P7–P9. It is possible that earlier treatment with either com-
poundmight reduce neuronal dysplasia, but any benefitmight be
offset by other growth and developmental consequences of
mTORC1 blockade.
Although spine density was significantly reduced (22%) in the
Tsc1null-neuron mice, there was no significant change in spine
length or morphology (qualitative observations only) in these
mice compared with controls. In response to rapamycin treat-
ment, there was only a modest increase (10%) in spine density
and a corresponding increase (9%) in spine length above normal,
suggesting that these dendritic morphologic abnormalities had
little direct importance for neuronal function in thismodel. Con-
versely, phosphorylated neurofilament, neurofilament heavy
chain, and neurofilament medium chain levels were all increased
in the Tsc1null-neuron mice and were reversed by rapamycin treat-
ment (Fig. 5B). In contrast to a previous report from in vitro slice
cultures (Tavazoie et al., 2005), we saw no significant change in
pCofilin(S3) levels in brain extracts from the Tsc1null-neuron mice,
suggesting that this actin regulatory protein had little to do with
the in vivo phenotype produced by loss of Tsc1 in neurons.
Our pharmacokinetic studies demonstrate that rapamycin/
RAD001 brain levels are approximately one-third that of sys-
temic levels at 48 h after the last dose, in both acute and chronic
treatment paradigms (Fig. 1A,B,D,E). These findings are consis-
tent with the clear treatment benefit noted. The buildup of each
drug that is seen over time in the brainmay serve as a reservoir for
slow release when treatment is discontinued. This phenomenon
may help to explain the prolonged symptom-free interval and
survival seen after drug withdrawal at P30 in the treated mice.
Although rapamycin/RAD001 levels achieved in these mice were
significantly higher than are typically sought in patients, it is no-
table that a lower dose of drug could have been used to achieve
both low therapeutic range brain levels (	5 ng/g) and concurrent
Figure 4. Improvement in myelination in Tsc1null-neuronmice treated with rapamycin. Each of the five columns of figures is taken from P45 control, P30 mutant (Tsc1null-neuron), P45 rapamycin-
treated mutant, and P45 rapamycin-treated until P30 then taken off drug (on/off) mutant, and P45 rapamycin-treated control, respectively. A–E, Myelin stain of the retrosplenial granular region
of cortex demonstrates that there is amarked reduction inmyelination in untreated Tsc1null-neuronmice, which improves with treatment, and thatmyelination in the on/off mice also begins to look
somewhatmorepatchy than inothergroups. Scalebar, 100m.All images capturedonNikon fluorescencemicroscopeat 60and constant exposure.F–J,Myelin stainof theCA3 regionof anterior
hippocampus shows similar findings to those in cortex. Scalebar, 100m.All images capturedonNikon fluorescencemicroscopeat constant exposure.K–O, Combinedmyelin (red)–pS6(S235/236)
(green) stain of CA3 region of hippocampus demonstrates that there are enlarged pS6 cells with reducedmyelin in this region in untreated mutant mice, both of which improve with rapamycin
treatment. pS6 expression and cell enlargement recur in the on/off treatedmutant mice. Scale bar, 20m. All images are Z-stacked 630 confocal images. Genotypes of mice were as follows: A,
E, F, J, K, O, Tsc1c SynICre; B, G, L, Tsc1c SynICre; C, D, H, I,M, N, Tsc1cc SynICre.
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high therapeutic range plasma levels (15–20 ng/ml). This is con-
sistent with more limited studies we have performed, in which
both rapamycin and RAD001 at 1 or 3 mg/kg given intraperito-
neally three times per week led to clear therapeutic benefit in this
model.
Loss of TSC1/TSC2 is now well known to lead to constitutive
elevation of rheb-GTP levels and consequent constitutive activa-
tion of mTORC1, which causes transcriptional effects to influ-
ence cell size increase and growth by phosphorylation and acti-
vation of S6 kinase and phosphorylation and inactivation of
eIF-4E binding protein 1. In addition to these direct or “down-
stream” effects, TSC1/TSC2 loss also leads to indirect (also
termed “feedback” or “upstream”) effects that limit the phos-
phorylation and activation of AKT (Zhang et al., 2003; Har-
rington et al., 2004; Shah et al., 2004). This is the first work to
demonstrate these complex effects of loss of Tsc1/Tsc2 in the
brain, with strong AKT downregulation seen concurrent with
activation of mTORC1. Rapamycin/RAD001 had prominent ac-
tivity in blocking both direct and indirect effects of mTORC1
activation, restoring Akt phosphorylation. Reduced AKT expres-
sion has been engineered in mice, although it is difficult because
of the existence of three different AKT isoforms with varying
expression levels in various tissues.Mice with significant (50% or
more) reduction in brain AKT expression have a significant phe-
notype withmicrocephaly and reduced numbers and size of neu-
rons, although neurologic and behavioral abnormalities have not
been investigated in detail (Easton et al., 2005; Tschopp et al.,
2005; Dummler et al., 2006). Reduced AKT expression leads to a
major (80–90%) reduction in pAKT(S473) levels in these brains,
whereas pTsc2 and pGSK3 levels were near normal (Dummler
et al., 2006). As we see the opposite clinical phenotype in the
Tsc1null-neuron mice, with brain and neuronal enlargement, it is
clear that these potential effects of AKT downregulation are over-
come by the effects of mTORC1 activation in the Tsc1null-neuron
mice. Nonetheless, as levels of pGSK3weremore reduced in the
Tsc1null-neuron brains than in AKT-deficient brains (Dummler et
al., 2006), it is possible that restoration of Akt function contrib-
uted significantly to the improvement in neurologic function
seen in the Tsc1null-neuron mice in response to treatment. Signifi-
cant concern has been raised by the possibility that elevation in
pAKT(S473) might occur because of rapamycin/RAD001 treat-
ment of malignancy, leading to a growth effect that could negate
the potential benefits of mTORC1 blockade (O’Reilly et al.,
2006). In this model, elevation of pAKT(S473) did occur in re-
sponse to these drugs, concurrent with a marked phenotypic and
histologic improvement, suggesting that it contributed to rather
than impeded the clinical response.
Finally, given the similarities between the cellular and patho-
logical abnormalities seen in this model and cortical tubers
(Meikle et al., 2007), these findings suggest the possibility that
rapamycin/RAD001 might have clinical benefit in the treatment
of TSC patients. Indeed, rapamycin has been shown to have sig-
nificant benefit, with shrinkage in size of TSC subependymal
4
trol, P30 mutant (Tsc1null-neuron), and P30 rapamycin-treated mutant and control (B) mice are
shown. B, Note reduction in elevated pS6(S240/244) levels as well as an increase in reduced
pS473–AKT and pS9–GSK3B levels of the mutant mice with treatment. C, In addition, abnor-
mal increases in phosphorylated neurofilament (pNF) and neurofilament heavy (NF-H) and
medium (NF-M) chains are reduced in response to rapamycin. Note that pCofilin(S3) levels are
not consistently different amongmutant and control mice. The untreated and treated controls
were all Tsc1c SynICre; untreated mutants were all Tsc1cc SynICre; treated mutants were
one Tsc1cc SynICre and two Tsc1c SynICre.
Figure5. Signalingand cytoskeletal effects of rapamycin treatment in Tsc1null-neuronmice.A,
Immunoblot analysis of brain lysates from P30 mutant (Tsc1null-neuron), P60 control, P60
rapamycin-treated mutant, and P60 rapamycin-treated until P30 then taken off drug (on/off).
Note that treatment-induced changes in both pS6 levels and in pAkt S473 levels reverse when
treatment is discontinued. * denotes Tsc1 protein band. All mutants were Tsc1c SynICre;
both controls were Tsc1c SynICre. B, C, Immunoblot analysis of brain lysates from P30 con-
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giant cell tumors (Franz et al., 2006). In addition, the brain pen-
etration shown here in P10 mice suggests that rapamycin would
also penetrate the CNS at high levels in infants. Therefore, these
drugs may possibly have benefit in the treatment of TSC-
associated infantile spasms, often a difficult clinical problem (Cu-
ratolo et al., 2006; Holmes and Stafstrom, 2007). Because similar
although not identical histologic features, including evidence of
mTORC1 activation and alteration of neurofilament expression,
are seen in focal cortical dysplasias (FCD) (Taylor et al., 2001;
Baybis et al., 2004; Miyata et al., 2004; Ljungberg et al., 2006),
rapamycin may possibly be of benefit in the treatment of neuro-
logical manifestations associated with FCD as well. However, it is
important to note that this model does not replicate the focal
nature of cortical tubers/FCD, nor their full spectrum of abnor-
mal cell types, including giant/balloon cells, so that translation of
these findings to patients should be considered carefully. In ad-
dition, potential major side effects of rapamycin/RAD001 in in-
fants and young children, including effects on growth as seen here
in mice that began treatment at P7, also mandates a cautious
approach to the investigation of the potential clinical translation
of these findings.
Note added in proof.Wedraw the reader’s attention to concurrent
work published recently by Zeng et al. (2008). These investigators
report that rapamycin is very effective in the treatment of amouse
astrocytemodel of TSCbased on this sameTsc1 conditional allele
(Uhlmann et al., 2002) with marked im-
provement in survival, epilepsy, and brain
pathology.
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